RAYS OF BELIEF LIMITED

Healthcare — Medical Care Facilities · NSE

₹281.20+₹31.78 (+12.74%)

DalalBaazaar Score

63 / 100

🟢 Good

Verdict

NEUTRAL

Risk

High

Driven by negative free cash flow, micro-cap size, which brings thin liquidity, a very high earnings multiple, which leaves little margin for disappointment.

In simple words: Strong business and financial position, though profits are falling even as sales grow. Cash generation is currently the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 6:10 pm

Caution warranted. Multiple fundamental metrics — flagged in red below — point to either valuation stretch, leverage risk, or weakening profitability. This doesn't mean avoid the stock outright, but it does mean the burden of proof is on the growth story to justify the current price.

Understanding the Business

Company site ↗

The 60-second version of RAYS OF BELIEF LIMITED — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Rays of Belief Limited operates as a holistic care provider for children with autism, ADHD, Down syndrome, and other developmental delays and disorders in India.

IndustryMedical Care Facilities

SectorHealthcare

Annual revenue₹82 Cr

How does it make money?

Turns over ₹82 Cr a year. Of every ₹100 of sales, about ₹6 reaches shareholders as profit, with ₹15 left at the operating level before interest, tax and depreciation.

EBITDA margin15.1%

Net margin6.1%

Who are its competitors?

The closest listed comparisons in its industry are APOLLO HOSPITALS ENTER. L, SUN PHARMACEUTICAL IND L, CIPLA LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

APOLLO HOSPITALS ENTER. LP/E 54.3x · ROE 22.0%

SUN PHARMACEUTICAL IND LP/E 34.9x · ROE 14.5%

CIPLA LTDP/E 31.8x · ROE 9.8%

What is its competitive advantage?Some evidence

ROCE of 21.5% is above what capital typically costs, which suggests some pricing power, though not yet the sustained, wide gap that marks a durable advantage.

ROCE21.5%

ROE16.1%

Peer median ROE14.5%

What has been driving growth?

Growth has come mainly from selling more, rather than from keeping more of each sale. Over 3 years revenue moved +269% while net margin moved -116% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect+269%

Margin effect-116%

DalalBaazaar Score

63/ 100

Good

Weighted across six categories. Every point is explained below.

✗ P/E of 71.0x is demanding — it needs sustained high growth to justify
✗ P/B of 14.17x is a steep premium to book

Quality vs. Valuation

Company Quality

77/ 100

Good

How good the business is, ignoring the share price entirely.

Valuation

24/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

A good business, but the price already reflects that. The quality is real; the question is whether you are overpaying for it today.

Historical Valuation

Current P/E

71.0x

Sector Median

34.9x

median of 3 sector peers

⚠️Against its sector it trades 103% above the peer median of 34.9x.

vs. its own history

Not enough price and earnings history

vs. sector peers

Expensive

34.9x median of 3 peers · +103%

vs. generic bands

Expensive

Above 35x

P/E (Trailing)

71.0x

P/B

14.17x

EV/EBITDA

48.1x

PEG

—

Dividend Yield

None

What's Good / What's Bad

🟢 What's Going Well4

Margins are improving
EBITDA margin is up from -31.7% to 15.1% over 3 years.
Return on equity is rising
ROE has improved from -194.1% to 16.1%.
Return on capital is rising
ROCE has improved from -164.5% to 21.5%.
High return on capital employed
ROCE of 21.5% is the mark of a business that converts capital into profit efficiently.

🔴 What Needs Attention3

Debt is rising
Total debt is up 560% over 3 years — worth checking what it funded.
Free cash flow is negative
The business is not currently covering its capital spending from operations.
Receivables growing faster than sales
Receivables are up 41009% against revenue growth of 269% — customers are taking longer to pay.

Red Flags

3 items require attention · 2 high · 1 watch

🔴Debt has risen sharplyFinancial
Total debt is up 560% over 3 years, from ₹1 Cr to ₹9 Cr.
🔴Receivables growing faster than salesFinancial
Receivables up 41009% against revenue up 269% — sales are being booked faster than they are collected.
🟡Free cash flow is negativeFinancial
Free cash flow was -₹3 Cr in the latest year.

Investment Thesis

🟢 Bull CaseWhat could make this work?

Capital compounds at a high rate
ROCE of 21.5% means each rupee reinvested earns well above what capital costs. If the company can keep deploying at this rate, growth creates value rather than just consuming cash.
Margin expansion has further to run
EBITDA margin has risen from -31.7% to 15.1%. If that holds, profit compounds faster than sales and today's multiple looks cheaper in hindsight than it does now.

🔴 Bear CaseWhat could go wrong?

Sales are being booked faster than collected
Receivables are up 41009% against revenue up 269%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
A premium to the sector to defend
It trades 103% above the peer median. That premium needs a reason that persists, or it closes.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.
Several serious flags at once
2 high-severity checks triggered. Individually each has an explanation; together they raise the chance that something structural is wrong rather than a one-off.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1Revenue growth stays above 41% a year✓ 54.5% CAGR
Latest reported year was 136.4%. The bar is set below the established compounding rate, so ordinary variation does not trip it.
2EBITDA margin holds above 13%✓ 15.1%
Two points below today's level — enough room for noise, tight enough to catch real compression.
3Free cash flow remains positive✗ -₹3 Cr
Profit that never becomes cash eventually stops being profit.
4Debt / EBITDA stays below 2x✓ 0.8x
The ratio lenders write covenants against; it survives a small or negative equity base, unlike Debt/Equity.
5ROCE stays above 18%✓ 21.5%
Falling returns on capital are usually competition arriving, and show up here before they reach the margin.

Investment Checklist

6 / 10 checks passed

✓ Strong return on equity (ROE ≥ 15%)
✓ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✗ Generates positive free cash flow
✓ Manageable leverage (Debt/Equity < 1.0)
✓ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✓ Revenue growing year-over-year
✗ Profit growing year-over-year
✗ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high

Price history

Quick Metrics

5 good · 2 neutral · 4 weak

Market Cap

₹588 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

71.0x

Expensive

Expensive — verify against sector peers

P/B Ratio

14.17x

Rich

Steep premium to book — needs high, durable returns to justify

EPS (TTM)

₹3.96

Profitable

Profitable on a per-share basis

ROE

16.1%

Strong

Strong capital efficiency

ROCE

21.5%

Strong

Earns comfortably above its likely cost of capital

Debt/Equity

0.30x

Low

Conservative leverage

Revenue Growth (YoY)

136.4%

Healthy

Healthy top-line growth

Profit Growth (YoY)

-24.6%

Falling

Profits are shrinking

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

-₹3 Cr

Cash burning

Spending more cash than the operations bring in

More Metrics

CMP

₹281.2

Operating Margin

15.6%

Good

Healthy core-business profitability

Net Margin

8.7%

Average

Average bottom-line conversion

Current Ratio

2.41

Comfortable

Healthy short-term liquidity

52W Range Position

82%

Mid-range

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹22 Cr	₹31 Cr	₹73 Cr	₹82 Cr	+54.5%
EBITDA	-₹7 Cr	₹2 Cr	₹4 Cr	₹12 Cr	—
EBITDA Margin	-31.7%	5.4%	5.3%	15.1%	—
PAT (Net Profit)	-₹8 Cr	₹1 Cr	₹7 Cr	₹5 Cr	—
EPS	₹-4.05	₹0.41	₹210.24	—	—
ROE	-194.1%	14.8%	37.5%	16.1%	—
ROCE	-164.5%	2.7%	6.4%	21.5%	—
Total Debt	₹1 Cr	₹2 Cr	₹9 Cr	₹9 Cr	+87.6%
Free Cash Flow	-₹8 Cr	₹1 Cr	-₹4 Cr	-₹3 Cr	—

🟢 Revenue has grown at 54.5% a year over 3 years.

🟢 EBITDA has turned positive, from -₹7 Cr to ₹12 Cr.

🟢 EBITDA Margin has risen from -31.7% to 15.1% over 3 years (+46.8 pts).

🟢 PAT (Net Profit) has turned positive, from -₹8 Cr to ₹5 Cr.

🟢 ROE has risen from -194.1% to 16.1% over 3 years (+210.2 pts).

🟢 ROCE has risen from -164.5% to 21.5% over 3 years (+186.0 pts).

🔴 Total Debt has grown at 87.6% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹51 Cr

Total Liabilities

₹20 Cr

Total Debt

₹9 Cr

Cash & Equivalents

₹3 Cr

Operating Cash Flow

-₹2 Cr

Capex

-₹1 Cr

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

73.5%

Peer Comparison

Company	P/E	ROE
APOLLO HOSPITALS ENTER. L	54.3x	22.0%
SUN PHARMACEUTICAL IND L	34.9x	14.5%
CIPLA LTD	31.8x	9.8%

Recent News

1 mixed5 general

Rays Of Belief Ltd. Share Price Rise Streak in Healthcare

Univest, 16 OctPrice move

🟡Mixed / dependsA price move, which is not by itself a change in the business. Worth finding the cause before reading it as either good or bad.

Flat debut: Rays of Belief shares list at issue price on NSE, BSE

Moneycontrol.com, 08 Sept

LRSD Capital reduces Rays of Belief stake to 4.16% via open market sale

scanx.trade, 14 Oct

Rays of Belief IPO Day 2: Subscription Status, Timeline & Key Issue Details

Groww, 02 Sept

Rays Of Belief Upper Circuit Today: Price, Data and Peers

Univest, 15 Oct

Compare with

Equitymaster, 17 Oct

Watch Items

Cross-check against the company's latest quarterly filing / investor presentation before acting.

DalalBaazaar Thesis

🟢Business QualityStrong15.4/20

🟢Financial HealthStrong13/20

🟢GrowthStrong18.4/20

🟢ProfitabilityStrong10.9/15

🔴ValuationDemanding3.2/15

🔴RiskHigh2.5/10

Good business, demanding price

The quality is real and the price already reflects it. Buying here is a bet that the business keeps compounding for long enough to grow into the multiple — which good businesses often do, but it removes the margin for error that a lower price would have given you. 2 high-severity red flags sit above this conclusion and should be read first.

This thesis breaks if

✓Revenue growth stays above 41% a year54.5% CAGR
✓EBITDA margin holds above 13%15.1%
✗Free cash flow remains positive-₹3 Cr
✓Debt / EBITDA stays below 2x0.8x
✓ROCE stays above 18%21.5%